= Discovery stage. (24.37%, 2023)
= Translation stage. (39.50%, 2023)
= Clinically available. (36.13%, 2023)
No entry found.
Financial Disclosure
Description
Y/N
Source
Grants
yes
MSACL
Salary
no
Board Member
no
Stock
no
Expenses
no
IP Royalty
no
Planning to mention or discuss specific products or technology of the company(ies) listed above:
no